# A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

> **NCT01810393** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 114 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01810393
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-11
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-17
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2020-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01810393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01810393, "A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01810393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*